Patents by Inventor Stephan D. Parent

Stephan D. Parent has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110301088
    Abstract: Crystalline ezatiostat hydrochloride ansolvate form D is more stable and/or more soluble that various solvated crystalline polymorphic forms of ezatiostat hydrochloride.
    Type: Application
    Filed: March 4, 2011
    Publication date: December 8, 2011
    Inventors: Stephan D. Parent, Steven R. Schow
  • Patent number: 8063227
    Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.
    Type: Grant
    Filed: July 14, 2009
    Date of Patent: November 22, 2011
    Assignee: Ferrokin Biosciences, Inc.
    Inventors: Amy E. Tapper, Hugh Y. Rienhoff, Jr., Stephan D. Parent, Patricia Andres, Jason A. Hanko, Huamin Zhang
  • Publication number: 20110245336
    Abstract: Disclosed are new colchicine solid complexes, methods of making the solid complexes as well as formulations prepared therefrom and uses thereof.
    Type: Application
    Filed: June 13, 2011
    Publication date: October 6, 2011
    Inventors: Tong Sun, David Jonaitis, Stephan D. Parent
  • Patent number: 8003700
    Abstract: Disclosed are new colchicine solid complexes, methods of making the solid complexes as well as formulation prepared therefrom and uses thereof.
    Type: Grant
    Filed: April 2, 2009
    Date of Patent: August 23, 2011
    Assignee: Mutual Pharamaceutical Company, Inc.
    Inventors: Tong Sun, David Jonaitis, Stephan D. Parent
  • Patent number: 7999110
    Abstract: The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2 -pyridinyl)-methyl]sulfinyl]-5-(1 H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a crystalline Form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.
    Type: Grant
    Filed: December 28, 2007
    Date of Patent: August 16, 2011
    Assignee: IL Yang Pharmaceutical Company, Ltd.
    Inventors: John M. Brackett, David T. Jonaitis, Wei Lai, Jih Hua Liu, Stephan D. Parent, Jinyu Shen
  • Patent number: 7989632
    Abstract: The invention relates to crystalline forms of various solvates of ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl)1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising crystalline ilaprazole hydrate according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.
    Type: Grant
    Filed: December 28, 2007
    Date of Patent: August 2, 2011
    Assignee: Il Yang Pharmaceutical Company, Ltd.
    Inventors: John M. Brackett, David T. Jonaitis, Wei Lai, Jih Hua Liu, Stephan D. Parent
  • Publication number: 20110160257
    Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.
    Type: Application
    Filed: March 7, 2011
    Publication date: June 30, 2011
    Applicant: FERROKIN BIOSCIENCES, INC.
    Inventors: Amy E. Tapper, Hugh Y. Rienhoff, JR., Stephan D. Parent, Patricia Andres, Jason A. Hanko, Huamin Zhang
  • Publication number: 20110082174
    Abstract: The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a crystalline Form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.
    Type: Application
    Filed: November 4, 2010
    Publication date: April 7, 2011
    Applicant: IL YANG PHARMACEUTICAL COMPANY, LTD.
    Inventors: John M. BRACKETT, David T. JONAITIS, Wei LAI, Jih Hua LIU, Stephan D. PARENT, Jinyu SHEN
  • Publication number: 20110046184
    Abstract: The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a crystalline Form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.
    Type: Application
    Filed: November 4, 2010
    Publication date: February 24, 2011
    Applicant: IL YANG PHARMACEUTICAL COMPANY, LTD.
    Inventors: John M. BRACKETT, David T. JONAITIS, Wei LAI, Jih Hua LIU, Stephan D. PARENT, Jinyu SHEN
  • Patent number: 7863276
    Abstract: Salt forms of potent modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.
    Type: Grant
    Filed: October 23, 2006
    Date of Patent: January 4, 2011
    Assignee: KALYPSYS, Inc
    Inventors: Dennis A. Bennett, Stephan D. Parent, David T. Jonaitis
  • Publication number: 20100137383
    Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.
    Type: Application
    Filed: July 14, 2009
    Publication date: June 3, 2010
    Applicant: FERROKIN BIOSCIENCES, INC.
    Inventors: Amy E. Tapper, Hugh Y. Rienhoff, JR., Stephan D. Parent, Patricia Andres, Jason A. Hanko, Huamin Zhang
  • Publication number: 20090326005
    Abstract: Disclosed are new quinine sulfate/bisulfate solid complexes, methods of making the solid complexes as well as formulations prepared therefrom and uses thereof.
    Type: Application
    Filed: June 25, 2009
    Publication date: December 31, 2009
    Inventors: Tong Sun, Shawn Watson, Wei Lai, Stephan D. Parent
  • Publication number: 20090253798
    Abstract: Disclosed are new colchicine solid complexes, methods of making the solid complexes as well as formulations prepared therefrom and uses thereof.
    Type: Application
    Filed: April 2, 2009
    Publication date: October 8, 2009
    Inventors: Tong Sun, David Jonaitis, Stephan D. Parent
  • Publication number: 20090131426
    Abstract: Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders are disclosed.
    Type: Application
    Filed: September 19, 2008
    Publication date: May 21, 2009
    Inventors: Shripad S. Bhagwat, Wei Lai, Stephan D. Parent, Melanie J. Roe, Alan Schwartz, Valeriya N. Smolenskaya
  • Publication number: 20090048204
    Abstract: A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior candidate for use, typically in solid dosage form, for treating a variety of disease states, generally associated with inflammation.
    Type: Application
    Filed: August 13, 2008
    Publication date: February 19, 2009
    Inventors: John Walling, Stephan D. Parent, David T. Jonaitis, Robert M. Kral, JR.
  • Publication number: 20080200516
    Abstract: The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a crystalline Form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.
    Type: Application
    Filed: December 28, 2007
    Publication date: August 21, 2008
    Applicant: TAP PHARMACEUTICAL PRODUCTS INC.
    Inventors: John M. BRACKETT, David T. JONAITIS, Wei LAI, Jih Hua LIU, Stephan D. PARENT, Jinyu SHEN
  • Publication number: 20080200517
    Abstract: The invention relates to crystalline forms of various solvates of ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising crystalline ilaprazole hydrate according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.
    Type: Application
    Filed: December 28, 2007
    Publication date: August 21, 2008
    Applicant: TAP PHARMACEUTICAL PRODUCTS INC.
    Inventors: John M. BRACKETT, David T. JONAITIS, Wei LAI, Jih Hua LIU, Stephan D. PARENT
  • Publication number: 20080200515
    Abstract: The invention relates to solid state forms of enantiopure ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfnyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a solid form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders such as those discussed above.
    Type: Application
    Filed: December 28, 2007
    Publication date: August 21, 2008
    Applicant: TAP PHARMACEUTICAL PRODUCTS INC.
    Inventors: John M. BRACKETT, David T. JONAITIS, Wei LAI, Jih Hua LIU, Stephan D. PARENT